Ustekinumab-stba (Steqeyma) now has FDA approval for all forms and dosages of its reference product, ustekinumab (Stelara), including a subcutaneous injection to treat pediatric patients with plaque psoriasis or psoriatic arthritis.
Search results for: psoriasis
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
Incarcerated Individuals with Rheumatic Conditions
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall
On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program, describing the benefits of apremilast and nintedanib for patients with rheumatic disease.
In the Details: Diagnosing PsA Requires Drilling Down
Rheumatologists must do some detective work into a patient’s signs and symptoms when considering a psoriatic arthritis diagnosis, according to Philip J. Mease, MD, MACR
Deucravacitinib Promising for PsA
Results from two studies found that deucravacitinib improved the signs and symptoms of patients with psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naive and those previously treated with a tumor necrosis factor α inhibitor.
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
ACR Image Competition 2024 Results, Part 3
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from Latin America and the Caribbean. Diagnosing Juvenile PsA A 13-year-old boy presented with a seven-year history of…
Chronic Back Pain & axSpA
Maksymowych et al. assessed the frequency of axial spondyloarthritis (axSpA) according to extra-articular presentation and human leukocyte antigen B27 (HLA-B27) status and sought to identify features that distinguish patients with axSpA from those with non-specific back pain. Their data support recommendations that patients with chronic back pain and extra-articular features related to axSpA be screened for axSpA with MRI and referred to a rheumatologist.
FDA Approves Bimekizumab-bkzx (Bimzelx) for 3 New Rheumatic Indications
The FDA has approved bimekizumab-bkzx for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 56
- Next Page »